- Home
- MPU vs ALZN Comparison
MPU vs ALZN Comparison
Compare MPU & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | ALZN |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPU | ALZN |
|---|---|---|
| Price | $1.26 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.5K | ★ 34.0K |
| Earning Date | 12-04-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.84 |
| 52 Week High | $3.88 | $2.56 |
Technical Indicators
Market Signals| Indicator | MPU | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 47.18 |
| Support Level | $0.62 | $1.20 |
| Resistance Level | $1.91 | $1.95 |
| Average True Range (ATR) | 0.21 | 0.15 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 8.22 | 41.96 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.